Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of avelumab in Japanese and Asian subjects with advanced solid tumors and gastric cancer
jRCT2080222945Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab in Nonhematologic neoplasms, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Merck KGaA. Primary endpoints: Tolerability and safety of avelumab, Pharmacokinetics of avelumab and 1 more. Started Aug 2015; status: completed.
02
Drugs
avelumab
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222945.